#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	17988	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2529	872.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1633	1633	C	1027	C,G	1025,2	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29786	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4188	886.2	0	.	n	.	0	T695C	SNP	695	695	T	1297	1297	C	1082	C,G	1080,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29786	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4188	886.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	1939	1939	A	1179	A,C	1177,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29786	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4188	886.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2573	2573	C	1060	C,T,G	1053,6,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29786	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4188	886.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2647	2647	A	1042	A,C	1039,2	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29786	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4188	886.2	1	SNP	n	C2597T	0	.	.	2597	2597	C	3199	3199	C	1061	C	1061	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2596	folP	852	852	100.0	folP.l15.c4.ctg.1	2236	144.5	1	SNP	p	R228S	1	.	.	682	684	AGC	1341	1343	AGC	257;254;251	A;G,C;C,A	257;253,1;250,1	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5926	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3980	185.5	1	SNP	p	S91F	0	.	.	271	273	TCC	843	845	TCC	231;230;231	T;C,A;C	231;229,1;231	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5926	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3980	185.5	1	SNP	p	D95N	0	.	.	283	285	GAC	855	857	GAC	225;221;220	G;A,C;C,A	225;220,1;219,1	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5926	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3980	185.5	1	SNP	p	D95G	0	.	.	283	285	GAC	855	857	GAC	225;221;220	G;A,C;C,A	225;220,1;219,1	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.Neisseria_meningitidis_MC58_v2_01735	mtrR.Neisseria_meningitidis_MC58_v2_01735	1	1	27	2402	mtrR	633	633	99.84	mtrR.l6.c30.ctg.1	2013	148.9	1	SNP	p	G45D	0	.	.	133	135	GGC	793	795	GGC	295;291;291	G;G;C	295;291;291	mtrR.Neisseria_meningitidis_MC58_v2_01735:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	432	mtrR_promoter	250	193	96.37	mtrR_promoter.l15.c4.ctg.1	1819	29.7	0	.	n	.	0	A125G	SNP	125	125	A	1010	1010	G	111	G	111	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	432	mtrR_promoter	250	193	96.37	mtrR_promoter.l15.c4.ctg.1	1819	29.7	0	.	n	.	0	C147T	SNP	147	147	C	1032	1032	T	122	T	122	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	432	mtrR_promoter	250	193	96.37	mtrR_promoter.l15.c4.ctg.1	1819	29.7	0	.	n	.	0	T159C	SNP	159	159	T	1044	1044	C	161	C	161	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	432	mtrR_promoter	250	193	96.37	mtrR_promoter.l15.c4.ctg.1	1819	29.7	0	.	n	.	0	C189T	SNP	189	189	C	1074	1074	T	148	T	148	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	432	mtrR_promoter	250	193	96.37	mtrR_promoter.l15.c4.ctg.1	1819	29.7	0	.	n	.	0	A192T	SNP	192	192	A	1077	1077	T	138	T,G	137,1	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	432	mtrR_promoter	250	193	96.37	mtrR_promoter.l15.c4.ctg.1	1819	29.7	0	.	n	.	0	A195C	SNP	195	195	A	1080	1080	C	134	C	134	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	432	mtrR_promoter	250	193	96.37	mtrR_promoter.l15.c4.ctg.1	1819	29.7	0	.	n	.	0	G221A	SNP	221	221	G	1106	1106	A	86	A	86	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5922	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3648	202.2	1	SNP	p	D86N	0	.	.	256	258	GAC	920	922	GAC	214;214;212	G;A,C;C,A	214;213,1;211,1	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5922	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3648	202.2	1	SNP	p	S87W	0	.	.	259	261	AGT	923	925	AGT	211;210;212	A,G;G;T,C	209,2;210;211,1	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5922	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3648	202.2	1	SNP	p	S87I	0	.	.	259	261	AGT	923	925	AGT	211;210;212	A,G;G;T,C	209,2;210;211,1	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5922	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3648	202.2	1	SNP	p	S87R	0	.	.	259	261	AGT	923	925	AGT	211;210;212	A,G;G;T,C	209,2;210;211,1	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5922	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3648	202.2	1	SNP	p	S88P	0	.	.	262	264	TCC	926	928	TCC	214;215;216	T,G,C;C;C	212,1,1;215;216	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4824	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3170	189.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1861	1863	GGC	274;271;272	G;G;C	273;270;272	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4612	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2990	192.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1581	1583	GCA	264;264;267	GC,G;C,A,G;A	254,1;262,1,1;267	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4612	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2990	192.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1584	1586	ATC	269;270;268	A;T,G;C,A	269;269,1;267,1	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4612	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2990	192.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1596	1598	GTG	264;264;267	G;T,G;G	264;263,1;267	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4612	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2990	192.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1596	1598	GTG	264;264;267	G;T,G;G	264;263,1;267	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4612	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2990	192.4	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2100	2102	ACC	248;248;247	A;C;C,G	248;248;246,1	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4612	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2990	192.4	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2154	2156	GCG	244;247;243	G,T;C;G,C	242,2;247;242,1	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4612	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2990	192.4	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2154	2156	GCG	244;247;243	G,T;C;G,C	242,2;247;242,1	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4612	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2990	192.4	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2277	2279	GGC	263;264;260	G,A;G;C,A	262,1;264;259,1	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4612	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2990	192.4	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2286	2288	GGC	259;260;262	G;G;C	259;260;262	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4612	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2990	192.4	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2304	2306	CCG	266;268;265	C,T;C;G,A	265,1;268;264,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6552	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3574	228.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2852	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2318	153.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	813	813	C	213	C,A	212,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	27	3540	porB1b	1047	1047	100.0	porB1b.l6.c4.ctg.1	2091	210.6	1	SNP	p	G120K	0	.	.	358	360	GGC	897	899	GGC	284;287;286	G,A;G;C	282,2;287;286	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	27	3540	porB1b	1047	1047	100.0	porB1b.l6.c4.ctg.1	2091	210.6	1	SNP	p	A121D	1	.	.	361	363	GAC	900	902	GAC	286;285;287	G,T;A,G;C	285,1;283,2;287	porB1b.WHO_P_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	27	3540	porB1b	1047	1047	100.0	porB1b.l6.c4.ctg.1	2091	210.6	1	SNP	p	D121N	0	.	.	361	363	GAC	900	902	GAC	286;285;287	G,T;A,G;C	285,1;283,2;287	porB1b.WHO_P_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11656	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5418	268.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1668	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1511	137.2	1	SNP	p	V57M	1	.	.	169	171	ATG	822	824	ATG	308;309;311	A;T;G,A	308;309;310,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
